<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008813</url>
  </required_header>
  <id_info>
    <org_study_id>2009-016226-13</org_study_id>
    <nct_id>NCT01008813</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)</brief_title>
  <official_title>A Randomized Phase II Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 1-year multicenter, randomized, single-blinded, phase II trial, stratified on HAART. The
      purpose of this trial is to evaluate the immunogenicity and safety of a A(H1N1)French
      National Agency for Research on AIDS and Viral Hepatitis influenza vaccine, administered with
      or without adjuvant, in HIV-infected patients after one or two injections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the immunogenicity and safety of a A(H1N1)v influenza vaccine, administered with or without adjuvant, in HIV-infected patients after two injections.</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety (local and general adverse events) between the two study vaccines</measure>
    <time_frame>From week 0 to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunogenicity of a A(H1N1)v influenza vaccine, administered with or without adjuvant, in HIV-infected patients receiving antiretroviral therapy or not</measure>
    <time_frame>Day 21 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the factors influencing the response to the vaccine (such as age, sex, tobacco use, HAART, CD4 count and nadir, HIV viral load, ...)</measure>
    <time_frame>From week 0 to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the sustainability of the immune response induced by two injections of the study</measure>
    <time_frame>Day 21 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the post-vaccinal cellular immune response of the two study vaccines</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the consequences of the A(H1N1)v influenza vaccine, with or without adjuvant, on the HIV infection parameters (CD4 count, HIV viral load)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess vaccination failures and describe the clinical presentation of influenza in the study population</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>adjuvanted A(H1N1)v influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two injections at day 0 and day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-adjuvanted A(H1N1)v influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two injection at day 0 and day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adjuvanted A(H1N1)v influenza vaccine</intervention_name>
    <description>Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (3,8 microgram) adjuvanted with AS 03A</description>
    <arm_group_label>adjuvanted A(H1N1)v influenza vaccine</arm_group_label>
    <other_name>Pandemrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>non-adjuvanted A(H1N1)v influenza vaccine</intervention_name>
    <description>Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (15 microgram)</description>
    <arm_group_label>non-adjuvanted A(H1N1)v influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Able to give written consent

          -  Covered by French Social Security

          -  HIV-infected (infection attested by the patient's chart)

          -  Patients treated by HAART for at least 6 months, with a viral load inferior to 50
             copies/mL on at least 2 last visits

          -  Patients without any treatment for HIV for at least 6 months and without any
             indication to start a treatment in the following 3 months

          -  Patients followed for their HIV-infection in an ANRS center and whose home is close to
             the center in case of influenza-like illness, consultation and hospitalization in the
             center where he is followed if necessary

          -  For women with childbearing potential, using an effective method of contraception, and
             willing to undergo urine pregnancy tests prior to each vaccination.

        Exclusion Criteria:

          -  Pregnancy

          -  Receipt of chemotherapy, immunotherapy (IL2, IL7, IV Ig), or corticosteroids within 3
             months prior to enrolment

          -  Thrombopenia inferior to 20 000/mm3

          -  Febrile episode (at least 38°C rectal or if at least 37,5°C measured orally) within
             one week prior to vaccination

          -  Opportunistic infection (treated for less than 1 month)

          -  Co-infection with HCV and treated with IFNa

          -  Influenza (clinically or virologically documented) in the last 6 months

          -  History of documented auto-immune disease (lupus, systemic inflammatory disease, ...)

          -  Child C cirrhosis

          -  Solid organ transplant recipient

          -  Intolerance to 1 component of the vaccine

          -  Other immunization received within 3 weeks prior to inclusion or planned until after
             the last vaccine injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Odile Launay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'investigation clinique de vaccinologie Cochin-Pasteur, Hôpital Cochin, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Kremlin Bicêtre Service de médecine interne</name>
      <address>
        <city>Kremlin Bicëtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales, Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC de Vaccinologie Cochin Pasteur, hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gustave Dron, Service Maladies Infectieuses</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>legal sponsor's website</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <last_update_submitted>December 21, 2011</last_update_submitted>
  <last_update_submitted_qc>December 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>adjuvanted and non-adjuvanted A(H1N1)v influenza vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

